H.R. 7867 · 119th Congress (2025–2027)
Infant Formula Safety Modernization Act of 2026
This bill directs the Food and Drug Administration (FDA) to expand requirements for the testing of infant formula and formula manufacturing facilities for pathogens and microorganisms.
Current regulations generally require manufacturers to test finished formula products for Cronobacter and Salmonella. The FDA tests manufacturing facilities for these contaminants in regular inspections, but manufacturers are not required to test their own facilities.
Within 90 days of the bill's enactment, the FDA must issue a final rule requiring manufacturers to test their facilities and finished formula products for certain pathogens and microorganisms, including Clostridium botulinum (which causes botulism). These regulations must include a recommended frequency for facilities testing, including requirements for testing different areas based on their proximity to formula products.
Manufacturers must notify the FDA within one business day of any positive result for one of the specified pathogens or microorganisms in a finished formula product, even if the product is still in the manufacturer’s possession. (Currently, notice is required only if the affected product has left the manufacturer’s facilities.) Manufacturers must also retain records of any positive result (from a test of formula or facilities).
The FDA must notify Congress within one business day of
- receiving notice of a positive test result for a finished formula product, or
- recommending official corrective action to address the findings of a facility inspection.
Finally, the regulations must explicitly require the FDA to enforce consistent inspection and compliance standards for all formula products, including imported products.
Show official title
To amend the Federal Food, Drug, and Cosmetic Act to establish standardized pathogen and microorganism testing of infant formula products and manufacturing facilities, to mandate notification of specific positive tests and inspection classifications, and for other purposes.
Referred to committee
Latest actionReferred to committee
This bill’s path
This is H.R. 7867’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
- Sponsor
- Rep. Rosa L. DeLauro (D-CT-3)
- Cosponsors
47 cosponsors
17 original · 30 later
4 R · 43 D
- Rep. Sanford D. Bishop, Jr. (D-GA-2)· Original · Mar 9, 2026
- Rep. Steve Cohen (D-TN-9)· Original · Mar 9, 2026
- Rep. Madeleine Dean (D-PA-4)· Original · Mar 9, 2026
- Rep. Adelita S. Grijalva (D-AZ-7)· Original · Mar 9, 2026
- Rep. Sara Jacobs (D-CA-51)· Original · Mar 9, 2026
- Rep. Raja Krishnamoorthi (D-IL-8)· Original · Mar 9, 2026
- Del. Eleanor Holmes Norton (D-DC)· Original · Mar 9, 2026
- Rep. Jimmy Panetta (D-CA-19)· Original · Mar 9, 2026
- Rep. Chris Pappas (D-NH-1)· Original · Mar 9, 2026
- Rep. Mike Quigley (D-IL-5)· Original · Mar 9, 2026
- Rep. Deborah K. Ross (D-NC-2)· Original · Mar 9, 2026
- Rep. Janice D. Schakowsky (D-IL-9)· Original · Mar 9, 2026
- Rep. Rashida Tlaib (D-MI-12)· Original · Mar 9, 2026
- Rep. Shri Thanedar (D-MI-13)· Original · Mar 9, 2026
- Rep. Jefferson Van Drew (R-NJ-2)· Original · Mar 9, 2026
- Rep. Nikema Williams (D-GA-5)· Original · Mar 9, 2026
- Rep. Frederica S. Wilson (D-FL-24)· Original · Mar 9, 2026
- Rep. Grace Meng (D-NY-6)· Later · Mar 18, 2026
- Rep. André Carson (D-IN-7)· Later · Apr 13, 2026
- Rep. Seth Magaziner (D-RI-2)· Later · Apr 20, 2026
- Rep. Ayanna Pressley (D-MA-7)· Later · Apr 27, 2026
- Rep. Julia Brownley (D-CA-26)· Later · May 12, 2026
- Rep. Lori Trahan (D-MA-3)· Later · May 12, 2026
- Rep. Jesús G. "Chuy" García (D-IL-4)· Later · May 20, 2026
- Rep. Melanie A. Stansbury (D-NM-1)· Later · May 20, 2026
- Rep. Michael Lawler (R-NY-17)· Later · Jun 22, 2026
- Rep. Seth Moulton (D-MA-6)· Later · Jun 22, 2026
- Rep. Debbie Wasserman Schultz (D-FL-25)· Later · Jul 13, 2026
- Rep. Suzanne Bonamici (D-OR-1)· Later · Jul 16, 2026
- Rep. Ted Lieu (D-CA-36)· Later · Jul 16, 2026
- Rep. LaMonica McIver (D-NJ-10)· Later · Jul 20, 2026
- Rep. Danny K. Davis (D-IL-7)· Later · Jul 21, 2026
- Rep. Jonathan L. Jackson (D-IL-1)· Later · Jul 21, 2026
- Rep. Teresa Leger Fernandez (D-NM-3)· Later · Jul 21, 2026
- Rep. Greg Landsman (D-OH-1)· Later · Jul 21, 2026
- Rep. Jamie Raskin (D-MD-8)· Later · Jul 21, 2026
- Rep. Robin L. Kelly (D-IL-2)· Later · Jul 22, 2026
- Rep. Betty McCollum (D-MN-4)· Later · Jul 22, 2026
- Rep. Suzan K. DelBene (D-WA-1)· Later · Aug 24, 2026
- Rep. Sarah Elfreth (D-MD-3)· Later · Aug 24, 2026
- Rep. Henry C. "Hank" Johnson, Jr. (D-GA-4)· Later · Aug 24, 2026
- Rep. Riley M. Moore (R-WV-2)· Later · Aug 24, 2026
- Rep. Eugene Simon Vindman (D-VA-7)· Later · Aug 24, 2026
- Rep. Brian K. Fitzpatrick (R-PA-1)· Later · Sep 10, 2026
- Rep. Christopher R. Deluzio (D-PA-17)· Later · Oct 22, 2026
- Rep. Mark DeSaulnier (D-CA-10)· Later · Oct 22, 2026
- Rep. Laura Friedman (D-CA-30)· Later · Oct 26, 2026
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Committees
Other meetings
Apr 29, 2026 · Hearing
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
Infant Formula Safety Modernization Act of 2026
Display title, Short title · Introduced in House
To amend the Federal Food, Drug, and Cosmetic Act to establish standardized pathogen and microorganism testing of infant formula products and manufacturing facilities, to mandate notification of specific positive tests and inspection classifications, and for other purposes.
Official title · Introduced in House